99 results
6-K
ASND
Ascendis Pharma A/S
2 May 24
Current report (foreign)
4:29pm
prepared in accordance with IFRS as issued by the International Accounting Standards Board (the “IASB”) and as adopted by the European Union (the “EU … Standards Board, and as adopted by the European Union, might differ in material respects from generally accepted accounting principles in other
6-K
EX-99.2
ASND
Ascendis Pharma A/S
2 May 24
Notice to convene Annual General Meeting 2024
4:02pm
Standards Board (“IASB”), and as adopted by the European Union (“EU”). The financial statements include additional disclosures for reporting class C large … States under its brand name SKYTROFA (lonapegsomatropin-tcgd). In addition, TransCon hGH was granted marketing authorization in the European Union (“EU
6-K
ASND
Ascendis Pharma A/S
24 Apr 24
Current report (foreign)
9:16am
in the European Union in November 2023. Orphan status provides 10 years of market exclusivity in Great Britain with respect to similar medicinal products
6-K
EX-99.1
gt0uaq9zd v9v
8 Jan 24
Current report (foreign)
6:08am
6-K
ric0hx
20 Nov 23
Current report (foreign)
4:01pm
6-K
2r8qdy
7 Nov 23
Current report (foreign)
4:03pm
6-K
EX-99.1
35925dmn
7 Nov 23
Ascendis Pharma Reports Third Quarter 2023 Financial Results
4:01pm
6-K
if55v
14 Sep 23
Current report (foreign)
12:42pm
6-K
kplg3 bxw
5 Sep 23
Current report (foreign)
4:14pm
6-K
EX-99.2
npkexn7jg0m6jiz9j6u
2 May 23
Notice to convene Annual General Meeting 2023
4:02pm
6-K
EX-99.3
ykheh47tx6k 0siqcv
2 May 23
Notice to convene Annual General Meeting 2023
4:02pm
6-K
rg8t67kh71ivn
27 Apr 23
Current report (foreign)
4:02pm
6-K
l4aki
2 Nov 22
Current report (foreign)
4:31pm
6-K
nuxcu
10 Aug 22
Current report (foreign)
4:13pm
6-K
EX-99.1
0fnq6d01c7 zb0vz4
11 May 22
Current report (foreign)
4:06pm
6-K
EX-99.2
fffexr
11 May 22
Current report (foreign)
4:06pm